

# Ana Carneiro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3266311/publications.pdf>

Version: 2024-02-01

31  
papers

2,354  
citations

471061

17  
h-index

476904

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020, 577, 561-565.	13.7	1,209
2	Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 581-592.	2.0	189
3	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309.	0.8	148
4	CR-mutated melanoma tumors harbor distinct clinical and biological characteristics. <i>Molecular Oncology</i> , 2017, 11, 438-451.	2.1	112
5	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. <i>Cancer Research</i> , 2016, 76, 4765-4774.	0.4	86
6	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. <i>Nature Communications</i> , 2021, 12, 5155.	5.8	85
7	Prognostic Impact of Array-based Genomic Profiles in Esophageal Squamous Cell Cancer. <i>BMC Cancer</i> , 2008, 8, 98.	1.1	77
8	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. <i>Cell Reports</i> , 2019, 27, 3573-3586.e7.	2.9	66
9	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , 2019, 19, 415.	1.1	49
10	A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. <i>Cancer</i> , 2011, 117, 1279-1287.	2.0	48
11	Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?. <i>Laboratory Investigation</i> , 2009, 89, 668-675.	1.7	42
12	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. <i>Cancers</i> , 2020, 12, 742.	1.7	38
13	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. <i>Molecular Oncology</i> , 2020, 14, 933-950.	2.1	29
14	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9504-9504.	0.8	23
15	Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. <i>Journal of Clinical Pathology</i> , 2011, 64, 689-694.	1.0	20
16	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9524-9524.	0.8	17
17	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. <i>Annals of Surgical Oncology</i> , 2019, 26, 2839-2845.	0.7	16
18	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. <i>Life Science Alliance</i> , 2020, 3, e202000893.	1.3	14

#	ARTICLE	IF	CITATIONS
19	Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome. <i>Familial Cancer</i> , 2014, 13, 537-545.	0.9	13
20	Rescue Effect Inherited in Colony Formation Assays Affects Radiation Response. <i>Radiation Research</i> , 2018, 189, 44-52.	0.7	10
21	A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3061-3061.	0.8	6
22	Surgery of metastatic melanoma after systemic therapy â€” the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta OncolÃ³gica</i> , 2021, 60, 52-55.	0.8	5
23	Discovery-Based Protein Expression Profiling Identifies Distinct Subgroups and Pathways in Leiomyosarcomas. <i>Molecular Cancer Research</i> , 2014, 12, 1729-1739.	1.5	4
24	Genetic Profiling Differentiates Second Primary Tumors from Metastases in Adult Metachronous Soft Tissue Sarcoma. <i>Sarcoma</i> , 2008, 2008, 1-7.	0.7	2
25	Prognostic value of proliferation in pleomorphic soft tissue sarcomas: a new look at an old measure. <i>Human Pathology</i> , 2012, 43, 2247-2254.	1.1	2
26	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9526-9526.	0.8	2
27	A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2646-2646.	0.8	1
28	17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcÎ³riib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
29	A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2653-TPS2653.	0.8	0
30	Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcÎ³riib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , 2021, 138, 1354-1354.	0.6	0
31	Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2529-2529.	0.8	0